ShangPharma Innovation

The firm concentrates on seed and Series A opportunities, writing checks into preclinical and early clinical-stage companies. Sectors include small-molecule therapeutics, biologics, diagnostics, and AI-driven drug discovery platforms. While specific check-size ranges are not publicly disclosed, the venture is structured to support capital-efficient biotech startups that can progress through preclinical proof-of-concept without immediately requiring large syndicates, in part because ShangPharma's infrastructure absorbs certain operational costs.

ShangPharma Innovation is the venture investing division of ShangPharma, the contract research organization founded in 2002 and headquartered in Shanghai. The parent company provides discovery chemistry, preclinical testing, formulation development, and clinical trial management to pharmaceutical clients globally. The venture arm invests independently but preferentially accesses the parent's service infrastructure for portfolio companies, creating a vertically integrated platform that spans early-stage venture capital through commercial drug development services.